Cross-Sector entity

Biofabrication

journal
7

Placenta-on-chip is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. The clearest coverage concentration is medical-devices: 1 of 2 stories, with the rest divided among 1 other category. Biofabrication appears in 2 tracked Cross-Sector stories from July 5, 2026.

2 verified stories tracked

Last mentioned: Jul 5, 2026

Entity pulse

Recent coverage · Biofabrication

2 stories
7 avg impact
100% positive
0% negative

Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.

  • 100% positive

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Biofabrication

Placenta-on-chip is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. The clearest coverage concentration is medical-devices: 1 of 2 stories, with the rest divided among 1 other category. Biofabrication appears in 2 tracked Cross-Sector stories from July 5, 2026. The tracked stories average 5 original sources each.

Stories tracked
2
Sources per story
5

Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Biofabrication. Shared-story counts are live from our verified record — not editorial picks.

Stories mentioning Biofabrication 2

Biotech pharma Positive 7

Indian Placenta-on-Chip Replicates 4 Functions for Drug R&D

Indian researchers have developed a placenta-on-chip that replicates four key maternal-fetal barrier functions—hormone production, glucose transport, urea clearance, and selective permeability—offering pharma a scalable tool for drug safety screening. The device’s response to hyperglycemic conditions mimics gestational diabetes, and its design using conventional well plates enables wide adoption across pharmaceutical R&D labs, potentially cutting costs and accelerating regulatory-required fetal toxicity assessments.

5 sources